Abnormal mass of tissue as a result of abnormal growth or division of cells
POPULARITY
Categories
Criminal Complaint Filed Over 'Warp Speed Cancer' (01:00:45 – 01:07:05)A complaint filed in France alleges mRNA vaccines caused deadly turbo cancers, implicating global health agencies while ignoring U.S. officials who enabled vaccine rollout. The term 'Warp Speed Cancer' is used to link aggressive cancers with the vaccine campaign.FDA Study Finds Excess DNA in COVID Vaccines (01:12:06 – 01:14:00)An FDA study confirms high levels of DNA contamination in Pfizer's mRNA vaccine, raising concerns over cancer risk and regulatory negligence. Critics compare the lax response to how pollution or car emissions would be handled.COVID Vaccine Removed from CDC Schedule for Children (01:25:54 – 01:27:49)RFK Jr. announces removal of COVID vaccines from the CDC schedule for healthy children and pregnant women, though skepticism is expressed over the true intent and lingering influence of vaccine advocates.CDC Panel Head Accused of Downplaying Vaccine Injuries (01:33:12 – 01:36:50)The new CDC vaccine panel head is criticized for opposing pauses on J&J shots and ignoring adverse event reports, leading to claims of pro-vaccine bias and lack of transparency about injury risks.Cargo Ship Fire Tied to EV Battery Hazards (01:53:00 – 01:59:30)An EV-laden cargo ship sinks after a prolonged fire, raising environmental concerns over lithium battery safety and whether such incidents are factored into EVs' environmental impact.Tesla Robo-Taxi Glitches Spark Regulatory Scrutiny (02:00:36 – 02:07:42)Videos show Tesla's driverless taxis behaving erratically, including stopping in intersections and veering off course. Observers criticize the premature rollout and ineffective safety measures.Markets Shrug Off U.S.-Israel Strike on Iran (02:25:30 – 02:27:04)Gold, silver, oil, and Bitcoin show minimal reaction to joint U.S.-Israel strikes, suggesting either disbelief in the severity of events or market manipulation by major financial actors.Christian Zionism Criticized as Political Idolatry (02:48:33 – 02:52:57)Christian Zionism is condemned as a distortion of theology, accused of leading believers to support war and foreign interventions at the expense of persecuted Christian communities.Pro-Israel Loyalty Test in Conservative Politics (02:52:58 – 03:01:38)Conservative figures are accused of prioritizing loyalty to Israel over American interests. A generational shift is predicted as younger conservatives push back against foreign entanglements.BIS vs IMF: Stablecoin Suppression and CBDC Agenda (03:01:39 – 03:03:04)The BIS targets stablecoins in what's described as a battle over who will control future digital money, with CBDCs positioned as tools of global financial dominance.Bitcoin Seen as Hedge Against Fiat Collapse (03:03:05 – 03:07:01)Extreme Bitcoin price forecasts are discussed in the context of fiat currency debasement, with Bitcoin framed as a finite refuge from an increasingly unstable monetary system.Self-Driving Cars as Surveillance and Control Tools (03:13:14 – 03:18:00)Explores how autonomous vehicles collect and transmit driver data, affect social credit scores, and raise concerns about accountability, privacy, and control.War Powers Debate: Trump, Iran, and Congressional Authority (03:18:01 – 03:24:17)Critiques Trump's bombing of Iran without Congressional approval and rebuts claims by Mike Johnson and J.D. Vance that the War Powers Resolution limits presidential authority.MAGA Civil War: Candace Owens vs. Trump on Vaccines and Israel (03:24:18 – 03:29:55) Candace Owens distances herself from Trump over foreign policy while she gave him a pass on Warp Speed vaccines, with commentary on her past praise and growing populist pushback.Trump's Nobel Peace Prize Nomination Mocked (03:30:40 – 03:31:35) Trump is nominated for a Nobel Peace Prize following the Iran ceasefire, provoking ridicule given his role in launching strikes days earlier.Mark Levin vs. Steve Bannon: Neocon Populist Feud over Israel (03:34:20 – 03:39:01)Levin calls for escalated military support for Israel, while Bannon and populist circles reject U.S. involvement. The rift signals deeper ideological divides on the right.Damage from Iranian Missile Strikes on Israel (03:45:10 – 03:47:55)Reports and footage highlight destruction caused by Iranian retaliation, while commentary accuses elites of profiting from wars at civilian expense.Iranian Officials Reported Dead Resurface (03:48:40 – 03:50:35) High-ranking Iranian figures previously declared dead by Israeli sources are shown to be alive, raising doubts about the success of targeted strikes.Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.
Support your health journey with our private practice! Explore comprehensive lab testing, functional assessments, and expert guidance for your wellness journey. Find exclusive offers for podcast listeners at nutritionwithjudy.com/podcast. _____Dr. Michael Karlfeldt and I sit down and talk about alternative cancer treatments. Is chemotherapy and radiation the best treatment? Is any food better than none while going through chemotherapy? What about exercise? Movement? Michael Karlfeldt, ND, PhD, has been in clinical practice since 1987 and runs an integrative medicine center, The Karlfeldt Center, in Boise, Idaho. Dr. Karlfeldt and his staff pride themselves on being compassionate cancer warriors focusing on cutting edge integrative cancer therapies working with international leaders to provide metabolic, genetic, and nutritional solutions to cancer while triggering cancer cell death through targeted oxidation. Dr. Karlfeldt's passion to promote Natural Health publicly has lead him to be a sought after lecturer, writer, and educator. Dr. Karlfeldt believes in the innate intelligence and healing power of the body and that if it is properly supported spiritually, emotionally and nutritionally it can find its way back to health. Dr. Karlfeldt IntroChemotherapy and Radiation for CancerImmune System's Role Post-Cancer TreatmentCancer Stem CellsIntegrative Cancer TherapyToxins, Tumors, and Genetics in CancerMost Common Toxins Turning on CancerDr. Karlfeldt and Chemo or Radiation for his Loved OnesThe Fear around CancerMitochondrial Health, Ketogenic Diets, DON, FastingWeight Loss with CancerFenbendazole, Ivermectin, Parasites, P53, Cell DeathProphylactic (Preventive) UseMind Body, Trauma and CancerThe Greatest Integrative Tool for CancerThe Biggest 3 Levers for CancerImportance of Muscle Mass_____EPISODE RESOURCES1) The Karlfeldt Center2) A Better Way to Cancer Book3) Integrative Cancer Solutions Podcast4) Integrative Lyme Solutions Podcast5) Dr. K Show Podcast6) NwJ's Private Practice_____WEEKLY NEWSLETTER
Criminal Complaint Filed Over 'Warp Speed Cancer' (01:00:45 – 01:07:05)A complaint filed in France alleges mRNA vaccines caused deadly turbo cancers, implicating global health agencies while ignoring U.S. officials who enabled vaccine rollout. The term 'Warp Speed Cancer' is used to link aggressive cancers with the vaccine campaign.FDA Study Finds Excess DNA in COVID Vaccines (01:12:06 – 01:14:00)An FDA study confirms high levels of DNA contamination in Pfizer's mRNA vaccine, raising concerns over cancer risk and regulatory negligence. Critics compare the lax response to how pollution or car emissions would be handled.COVID Vaccine Removed from CDC Schedule for Children (01:25:54 – 01:27:49)RFK Jr. announces removal of COVID vaccines from the CDC schedule for healthy children and pregnant women, though skepticism is expressed over the true intent and lingering influence of vaccine advocates.CDC Panel Head Accused of Downplaying Vaccine Injuries (01:33:12 – 01:36:50)The new CDC vaccine panel head is criticized for opposing pauses on J&J shots and ignoring adverse event reports, leading to claims of pro-vaccine bias and lack of transparency about injury risks.Cargo Ship Fire Tied to EV Battery Hazards (01:53:00 – 01:59:30)An EV-laden cargo ship sinks after a prolonged fire, raising environmental concerns over lithium battery safety and whether such incidents are factored into EVs' environmental impact.Tesla Robo-Taxi Glitches Spark Regulatory Scrutiny (02:00:36 – 02:07:42)Videos show Tesla's driverless taxis behaving erratically, including stopping in intersections and veering off course. Observers criticize the premature rollout and ineffective safety measures.Markets Shrug Off U.S.-Israel Strike on Iran (02:25:30 – 02:27:04)Gold, silver, oil, and Bitcoin show minimal reaction to joint U.S.-Israel strikes, suggesting either disbelief in the severity of events or market manipulation by major financial actors.Christian Zionism Criticized as Political Idolatry (02:48:33 – 02:52:57)Christian Zionism is condemned as a distortion of theology, accused of leading believers to support war and foreign interventions at the expense of persecuted Christian communities.Pro-Israel Loyalty Test in Conservative Politics (02:52:58 – 03:01:38)Conservative figures are accused of prioritizing loyalty to Israel over American interests. A generational shift is predicted as younger conservatives push back against foreign entanglements.BIS vs IMF: Stablecoin Suppression and CBDC Agenda (03:01:39 – 03:03:04)The BIS targets stablecoins in what's described as a battle over who will control future digital money, with CBDCs positioned as tools of global financial dominance.Bitcoin Seen as Hedge Against Fiat Collapse (03:03:05 – 03:07:01)Extreme Bitcoin price forecasts are discussed in the context of fiat currency debasement, with Bitcoin framed as a finite refuge from an increasingly unstable monetary system.Self-Driving Cars as Surveillance and Control Tools (03:13:14 – 03:18:00)Explores how autonomous vehicles collect and transmit driver data, affect social credit scores, and raise concerns about accountability, privacy, and control.War Powers Debate: Trump, Iran, and Congressional Authority (03:18:01 – 03:24:17)Critiques Trump's bombing of Iran without Congressional approval and rebuts claims by Mike Johnson and J.D. Vance that the War Powers Resolution limits presidential authority.MAGA Civil War: Candace Owens vs. Trump on Vaccines and Israel (03:24:18 – 03:29:55) Candace Owens distances herself from Trump over foreign policy while she gave him a pass on Warp Speed vaccines, with commentary on her past praise and growing populist pushback.Trump's Nobel Peace Prize Nomination Mocked (03:30:40 – 03:31:35) Trump is nominated for a Nobel Peace Prize following the Iran ceasefire, provoking ridicule given his role in launching strikes days earlier.Mark Levin vs. Steve Bannon: Neocon Populist Feud over Israel (03:34:20 – 03:39:01)Levin calls for escalated military support for Israel, while Bannon and populist circles reject U.S. involvement. The rift signals deeper ideological divides on the right.Damage from Iranian Missile Strikes on Israel (03:45:10 – 03:47:55)Reports and footage highlight destruction caused by Iranian retaliation, while commentary accuses elites of profiting from wars at civilian expense.Iranian Officials Reported Dead Resurface (03:48:40 – 03:50:35) High-ranking Iranian figures previously declared dead by Israeli sources are shown to be alive, raising doubts about the success of targeted strikes.Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.
BUFFALO, NY – June 24, 2025 – A new precision #oncology paper was #published in Volume 16 of Oncotarget on June 17, 2025, titled “Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment.” In this report, led by Alberto Hernando-Calvo from Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology; Razelle Kurzrock from WIN Consortium and Medical College of Wisconsin; Oncotarget Editor-in-Chief Wafik S. El-Deiry from WIN Consortium and Legorreta Cancer Center at Brown University; and corresponding author Shai Magidi, also from WIN Consortium, along with colleagues, describe the case of a 62-year-old man with metastatic colorectal cancer who underwent multiple lines of therapy. After analysis, the WIN International Molecular Tumor Board proposed different personalized treatment plans based on the tumor's unique genetic mutations. This case highlights the growing role of precision oncology in guiding therapies for patients with treatment-resistant cancers. Colorectal cancer is one of the deadliest cancers worldwide, and managing advanced cases remains a significant challenge. This patient had already received five prior treatment regimens, including chemotherapy and targeted therapies. Although some treatments were initially beneficial, the cancer eventually developed resistance. Molecular analysis revealed key mutations in genes such as BRAF, MET, APC, TP53, and NRAS, which are often linked to aggressive tumor behavior and reduced treatment effectiveness. With limited standard options left, the patient's case was presented and reviewed by the WIN International Molecular Tumor Board, a global panel of cancer experts. The team analyzed the clinical history and genetic profile to design new treatment approaches. These involved off-label drug combinations tailored to the specific mutations found in the tumor. For example, one approach combined trametinib, a drug that blocks cancer cell growth signals, with amivantamab, an antibody that attacks cancer-related proteins MET and EGFR, and regorafenib, which helps cut off blood supply to tumors and may counteract effects from APC and TP53 mutations. “Another option was trametinib at 1 mg daily, cetuximab (EGFR antibody), 250 mg/m² IV every two-weeks, and cabozantinib (MET and VEGFR inhibitor), 40 mg po daily.” This case reflects a shift in cancer care from standardized protocols to precision approaches, where therapy is selected based on a tumor's molecular features. Such strategies aim to delay resistance and slow disease progression more effectively. The WIN International Molecular Tumor Board also discussed practical challenges, including access to medications, combining off-label drugs, and the difficulties of enrolling patients in clinical trials after multiple prior treatments. Although the ultimate treatment decision remained with the patient's physician, this report shows how international collaboration and precision oncology can expand options for patients facing limited alternatives. It also emphasizes the value of repeat genetic analysis during disease progression to monitor new mutations in the tumor that may impact treatment. While the patient ultimately died from cancer progression, this case serves as a model for how molecular analysis and expert input can be used to guide treatment even in complex and metastatic colorectal cancer. As personalized cancer strategies continue to evolve, they may offer potential pathways for patients who have exhausted standard treatment options. DOI - https://doi.org/10.18632/oncotarget.28744 Correspondence to - Shai Magidi - shai.magidi@winconsortium.org Video short - https://www.youtube.com/watch?v=uWDtWNgpK7A To learn more about Oncotarget, please visit https://www.oncotarget.com. MEDIA@IMPACTJOURNALS.COM
Mismatch repair is just what it sounds like: when a cell divides and makes new DNA strands when a mistake is made it repairs them. Some types of cancers with a mismatch repair mutation may now be treated with an … Different types of tumors with a specific mutation may not need surgery, Elizabeth Tracey reports Read More »
What happens when you're told your child has over 1,000 tumors—and there's nothing more doctors can do? In this powerful episode, we sit down with Nat and Daniel Nowak to hear the miraculous healing story of their son Murphy, who was diagnosed with stage 4 high-risk neuroblastoma. Against all odds, and through a journey marked by faith, prayer, and relentless love, Murphy's body defied every expectation.This conversation is a testimony to the power of hope and the God who still heals. Whether you're in a season of doubt or simply need your faith stirred, this episode will move you deeply.
Recorded by Kaveh Akbar for Poem-a-Day, a series produced by the Academy of American Poets. Published on June 16, 2025. www.poets.org
»Metoda je zelo prijazna pacientom in lahko si predstavljate, kako z njo od znotraj obsevamo tumorsko tkivo.«Radioembolizacija je posebna in učinkovita metoda za odstranjevanje rakavega tkiva. Prim. prof. dr. Martin-Michael Uggowitzer vodi Inštitut za radiologijo in nuklearno medicino v Deželni bolnišnici LKH Leoben na avstrijskem Štajerskem. Pravi, da so lani s postopkom radioembolizacije zdravili 15 bolnic in bolnikov s turskimi tvorbami v jetrih. Pričakuje, da bo letos ta številka še višja. Tovrstno terapijo v Avstriji ob Leobnu izvajajo še trije ali štirje medicinski centri, v Sloveniji pa ljubljanski Klinični center. Tako kot v Avstriji stroške radioembolizacije tudi v Sloveniji krije zdravstvena zavarovalnica. Podrobneje v Ultrazvoku.
What do you do when cancer is always present in your family? David Mauk lost his mother, his sister, and other loved ones to breast cancer. He knows what it's like to grow up surrounded by the reality of cancer and to carry the BRCA gene. In today’s episode, you’ll hear: How genetic testing changed the choices his family made What it feels like to be a cancer advocate in Washington, D.C. Why sharing your family history can help save lives Support The Rose HERE. Subscribe to Let’s Talk About Your Breasts on Apple Podcasts, Spotify, iHeart, and wherever you get your podcasts. Key Questions Answered What impact did breast cancer have on David Mauk's family? What is the significance of the BRCA gene in David’s family? How did David’s family talk about breast cancer while he was growing up? How did David cope with losing his mother at such a young age? Did David himself undergo genetic testing and what were the results? How does David’s family approach genetic testing and health surveillance today? What has David done as an advocate for cancer research and awareness? Why does David believe early detection and knowing your family history is so crucial? What advice does David have for those with a family history of cancer? How has cancer research and treatment changed since previous generations? Timestamped Overview 00:00 Family, Cancer, Advocacy, Gene Awareness 04:31 Air Force Headsets Linked to Tumors 07:36 "Air Force Brat’s Journey" 11:07 Cancer Society Fundraising Champions 14:11 "Make Cancer Conversations Personal" 15:41 "Missing Maternal Memories" 22:00 Family Migration Journey 22:57 Living Positively Amidst Fear 25:57 Discovering Family Through DNA Insights 29:37 Empowering Young Women Against Breast CancerSee omnystudio.com/listener for privacy information.
Cancer-fighting implant shows promise in treating melanoma, pancreatic and colorectal tumors. Rice-led study serves as foundation for FDA investigational new drug application and emerging new company to launch from RBL LLC. Veiseh's team at Rice University has created an implant that functions like a “cytokine factory,” delivering IL-12 — a powerful immune-stimulating molecule — directly into the tumor environment. This approach boosts the body's ability to fight cancer while avoiding the severe side effects usually associated with systemic IL-12 therapy.
A mysterious disease called acute flaccid myelitis (AFM) has been appearing in emergency rooms for about a decade. The disease has caused otherwise healthy children to lose the ability to move their arms and legs, and some become completely paralyzed. AFM is caused by a virus that's a cousin of the polio virus, earning it the nickname "the new polio.” Journalist and physician Eli Cahan joins Host Flora Lichtman to explain what doctors have been observing, the research efforts toward developing a vaccine, and what this emerging disease reveals about our readiness for future outbreaks and pandemics.Read Cahan's article about what fighting this “new polio” might look like as our healthcare infrastructure gets dismantled.And, learning more about some non-cancerous cells may help researchers better understand how cancer progresses. When you think about how cancer spreads in the body, you're probably thinking about cancer cells—they divide uncontrollably, form into tumors, and hide from the immune system. So, it makes sense that studying the behavior of these cells is critical to our understanding of cancer. But now, researchers are looking more closely at the non-cancerous cells that co-exist within tumors and the surrounding tissues. They make up what's called the “colocateome.” Taking this more holistic approach to cancer research may help explain why some treatments don't work for all patients, and eventually may lead to more effective therapies. To better understand this expanding field, Host Ira Flatow talks with Sylvia Plevritis, a Stanford University cancer researcher. Guests:Dr. Eli Cahan is a journalist and physician based in Boston, Massachusetts.Dr. Sylvia Plevritis is a professor of biomedical data science and radiology at Stanford University.Transcript is available on sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.
Support the show: http://www.newcountry963.com/hawkeyeinthemorningSee omnystudio.com/listener for privacy information.
Welcome to Season 2 of the Orthobullets Podcast.Today's show is Foundations, where we review foundational knowledge for frontline MSK providers such as junior orthopaedic residents, ER physicians, and primary care providers.This episode will cover the topic of Giant Cell Tumor, from our Pathology section at Orthobullets.com.Follow Orthobullets on Social Media:FacebookInstagram TwitterLinkedInYouTube
William Lowry, Ph.D., discusses manipulating metabolic pathways in hair follicle stem cells to inhibit tumorigenesis. By blocking glycolysis and glutamine lysis simultaneously, they observed tumor regression, highlighting the complex interplay between metabolism and cancer. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39256]
William Lowry, Ph.D., discusses manipulating metabolic pathways in hair follicle stem cells to inhibit tumorigenesis. By blocking glycolysis and glutamine lysis simultaneously, they observed tumor regression, highlighting the complex interplay between metabolism and cancer. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39256]
William Lowry, Ph.D., discusses manipulating metabolic pathways in hair follicle stem cells to inhibit tumorigenesis. By blocking glycolysis and glutamine lysis simultaneously, they observed tumor regression, highlighting the complex interplay between metabolism and cancer. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39256]
William Lowry, Ph.D., discusses manipulating metabolic pathways in hair follicle stem cells to inhibit tumorigenesis. By blocking glycolysis and glutamine lysis simultaneously, they observed tumor regression, highlighting the complex interplay between metabolism and cancer. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39256]
William Lowry, Ph.D., discusses manipulating metabolic pathways in hair follicle stem cells to inhibit tumorigenesis. By blocking glycolysis and glutamine lysis simultaneously, they observed tumor regression, highlighting the complex interplay between metabolism and cancer. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39256]
William Lowry, Ph.D., discusses manipulating metabolic pathways in hair follicle stem cells to inhibit tumorigenesis. By blocking glycolysis and glutamine lysis simultaneously, they observed tumor regression, highlighting the complex interplay between metabolism and cancer. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39256]
William Lowry, Ph.D., discusses manipulating metabolic pathways in hair follicle stem cells to inhibit tumorigenesis. By blocking glycolysis and glutamine lysis simultaneously, they observed tumor regression, highlighting the complex interplay between metabolism and cancer. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39256]
In this podcast episode of Integrative Cancer Solutions Dr. Karlfeldt interviews Dr. Chris Apfel about his integrative approaches to cancer treatment. Dr. Apfel shares his journey from traditional medicine to integrative oncology, sparked by his father's lung cancer diagnosis. This personal experience led him to question conventional cancer treatments after learning about their low success rates, particularly for stage four lung cancer. Dr. Apfel discusses his development of the Onca test, which can identify effective cancer therapies within a week by culturing tumor fragments. This test evaluates a wide range of treatments including chemotherapies, targeted therapies, and repurposed drugs. He emphasizes the importance of avoiding ineffective treatments that can harm the immune system and diminish quality of life, while highlighting the potential of repurposed drugs like statins, Metformin, and Itraconazole. The conversation addresses tumor heterogeneity and the need for representative biopsy samples, particularly from metastatic sites. Dr. Apfel explains that the Onca test is commercially available, with discounts offered to patients willing to share their data for research purposes. He discusses various methods for obtaining tumor samples and the importance of timing in the collection process.Dr. Apfel emphasizes patient advocacy and the need for patients to be informed about their treatment options. He notes that the Onca test can double the odds of a positive tumor response and significantly increase median survival rates. The podcast concludes with Dr. Apfel expressing interest in collaborating with Dr. Folt's center to help more cancer patients through this innovative approach to personalized cancer treatment.About Dr Chris Apfel:Chris Apfel, MD, PhD, MBA is a physician and clinical researcher with over 100 published papers, including a six-factor clinical prediction model published in NEJM that led to the development of The Apfel Score, a clinical calculator used universally to predict the risk of postoperative nausea and vomiting, and Dr Apfel's ultimate recruitment to the US and the University of California, San Francisco.Dr. Apfel was driven to revolutionize the field of cancer patient treatment after losing his mother to a long battle with ovarian cancer and his father to lung cancer. Witnessing their suffering inspired him leave the clinical department at UCSF to develop more efficient ways to identify the best treatment plans for cancer patients.Dr Apfel received his MD and PhD from the University of Giessen in Germany and his MBA from Wharton at the University of Pennsylvania. He is the founder and CEO of SageMedic.Dr. Apfel developed the Onca test, which can identify effective cancer therapies within a week by culturing tumor fragments, potentially doubling the odds of positive tumor response.Personal experience with his father's lung cancer led Dr. Apfel to question conventional treatments after discovering their low success rates for advanced cancers.The Onca test evaluates chemotherapies, targeted therapies, and repurposed drugs like statins and Metformin, which have shown promising results in cancer treatment.Tumor heterogeneity makes it crucial to obtain representative biopsy samples, particularly from metastatic sites, to avoid ineffective treatments.Patient advocacy is essential in cancer treatment, as patients need to make informed decisions about tissue handling before surgery and find oncologists willing to consider alternative treatments based on test results.----Grab my book A Better Way to Treat Cancer: A Comprehensive Guide to Understanding, Preventing and Most Effectively Treating Our Biggest Health Threat - https://www.amazon.com/dp/B0CM1KKD9X?ref_=pe_3052080_397514860 Unleashing 10X Power: A Revolutionary Approach to Conquering Cancerhttps://store.thekarlfeldtcenter.com/products/unleashing-10x-power-Price: $24.99-100% Off Discount Code: CANCERPODCAST1Healing Within: Unraveling the Emotional Roots of Cancerhttps://store.thekarlfeldtcenter.com/products/healing-within-Price: $24.99-100% Off Discount Code: CANCERPODCAST2----Integrative Cancer Solutions was created to instill hope and empowerment. Other people have been where you are right now and have already done the research for you. Listen to their stories and journeys and apply what they learned to achieve similar outcomes as they have, cancer remission and an even more fullness of life than before the diagnosis. Guests will discuss what therapies, supplements, and practitioners they relied on to beat cancer. Once diagnosed, time is of the essence. This podcast will dramatically reduce your learning curve as you search for your own solution to cancer. To learn more about the cutting-edge integrative cancer therapies Dr. Karlfeldt offer at his center, please visit www.TheKarlfeldtCenter.com
Beating Cancer Daily with Saranne Rothberg ~ Stage IV Cancer Survivor
Today on Beating Cancer Daily, Saranne tackles the lighter side of living with Stage IV cancer by sharing one of her own humorous takes from her 31-day "Can We Laugh at Cancer" humor challenge. Drawing on her personal experience of 30 years beating Stage IV cancer and her journey as a single mom enduring treatment, Saranne highlights the challenges of chemo brain, especially in high-pressure situations like job interviews. Through laughter, reflection, and listener engagement, she encourages the community to adopt a comic perspective for resilience and stress relief. "It helps build your resiliency. It helps you when things are stressful and awful and yucky like they were for me..." ~SaranneToday on Beating Cancer Daily:· Laughter is a powerful coping mechanism, even during cancer treatment.· Chemo brain is a real and recognized side effect of chemotherapy.· Humor can help build resilience and manage stress throughout the cancer journey.· Job interviews while experiencing chemo brain can lead to funny and relatable moments.· Saranne encourages listeners to contribute their own jokes or stories about cancer and chemo brain.· The world has become more aware of chemo brain thanks to scientific research.· Using humor can be a gentle way to acknowledge memory lapses during or after treatment. Ranked the Top 5 Best Cancer Podcasts by CancerCare News in 2024 & 2025, and #1 Rated Cancer Survivor Podcast by FeedSpot in 2024 Beating Cancer Daily is listened to in over 130 countries on 7 continents and has over 365 original daily episodes hosted by Stage IV survivor Saranne Rothberg! To learn more about Host Saranne Rothberg and The ComedyCures Foundation:https://www.comedycures.org/ To write to Saranne or a guest:https://www.comedycures.org/contact-8 To record a message to Saranne or a guest:https://www.speakpipe.com/BCD_Comments_Suggestions To sign up for the free Health Builder Series live on Zoom with Saranne and Jacqui, go to The ComedyCures Foundation's homepage:https://www.comedycures.org/ Please support the creation of more original episodes of Beating Cancer Daily and other free ComedyCures Foundation programs with a tax-deductible contribution:http://bit.ly/ComedyCuresDonate THANK YOU! Please tell a friend whom we may help, and please support us with a beautiful review. Have a blessed day! Saranne
Marlene ist gerade glücklich im 6. Monat schwanger, da erfährt sie: Sie hat einen aggressiven, meist tödlichen Hirntumor. Doch eine medizinische Studie macht ihr wieder Hoffnung.
Dr. John Sweetenham shares highlights from Day 2 of the 2025 ASCO Annual Meeting, including new data on the treatment of ER+/HER2-negative breast cancer and potentially practice-changing results for patients with cutaneous squamous cell carcinoma at high risk of recurrence. Transcript Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham, your host of the ASCO Daily News Podcast, welcoming you to our special coverage of the 2025 ASCO Annual Meeting. Today, I'll be bringing you my takeaways on selected abstracts from Day 2 of the Meeting. My disclosures are available in the transcript of this episode. Today's selection features important, new data on the treatment of ER-positive, HER2-negative breast cancer, the use of tumor treating fields in combination with chemotherapy for locally advanced pancreatic cancer, and potentially practice-changing results for patients with cutaneous squamous cell carcinoma at high-risk of recurrence. Our first selected abstract is LBA1000. This important phase 3 study was presented by Dr. Erika Hamilton from the Sarah Cannon Research Institute in Nashville and evaluated the use of a novel agent, vepdegestrant, in patients with ER-positive/HER2-negative breast cancer, which had progressed after first-line endocrine therapy. Vepdegestrant is a selective oral PROTAC estrogen receptor degrader, which targets wild-type and mutant estrogen receptor through a novel mechanism of action which directly harnesses the ubiquitin-proteasome system to degrade ER. It has potential advantages over fulvestrant, a selective ER degrader which has to be administered intramuscularly and has limited benefit in patients who progress after endocrine therapy plus a CDK4/6 inhibitor. Building on the encouraging results from the initial phase 1/2 study of vepdegestrant, Dr. Hamilton reported results from the VERITAC-2 global phase 3 trial, comparing this agent with fulvestrant. The patients in the study had already received treatment with hormone therapy and a CDK inhibitor and were randomly assigned to receive treatment with either vepdegestrant (313 patients) or fulvestrant (311 patients). The vepdegestrant was taken orally each day, while the fulvestrant was given intramuscularly on days 1 and 15 of the first cycle of treatment and day 1 of each subsequent treatment cycle. Patients were stratified by the presence of wild-type ER or ESR1 mutation. A total of 43.3% of patients had ESR1 mutations; 136 of those were in the vepdegestrant group and 134 in the fulvestrant group. For patients with ESR1 mutations, vepdegestrant significantly increased progression-free survival compared with fulvestrant. For patients who received vepdegestrant, the median PFS was 5 months versus 2.1 months for those who received fulvestrant. The clinical benefit rate was 42.1% in the vepdegestrant group vs. 20.2% in the fulvestrant group. The overall response rate was 18.6% in the vepdegestrant group compared with only 4% in the fulvestrant group. The PFS and response benefits of vepdegestrant were largely restricted to the population with ESR1 mutations. Overall survival data are currently immature. The safety profile was favorable, with fewer than 5% of patients having dose reductions or discontinuation due to toxicity. The most frequent toxicities were fatigue, nausea, and elevated transaminases. The authors concluded that oral vepdegestrant demonstrates statistically significant and clinically meaningful improvement in progression-free survival compared with fulvestrant in this group of patients with ESR1-mutated ER+/HER2- advanced breast cancer who have progressed after endocrine therapy and a CDK inhibitor. Patients with recurrent disease in this context are now routinely tested for ESR1 mutations, and this agent is for sure a potential treatment option for them. The next study on today's episode, LBA4005, reports on the use of tumor treatment fields for patients with locally advanced pancreatic cancer. Tumor treatment fields are electric fields which disrupt cell division and may also induce an enhanced immune response, using a non-invasive portable device attached to the skin, and are already approved for the treatment of some cancers, including GBM and non-small cell lung cancer. A previous phase 2 trial, PANOVA-2, confirmed the feasibility and safety of using this approach in combination with gemcitabine plus or minus nabpaclitaxel in pancreatic cancer. In today's presentation, Dr. Vincent Picozzi from the Virginia Mason Medical Center in Seattle presented the results of the PANOVA-3 trial, a phase 3 study comparing gemcitabine and nabpaclitaxel with the same chemotherapy plus tumor treatment fields in patients with locally advanced pancreatic adenocarcinoma. Five hundred and seventy-one eligible patients were enrolled in the study with a total of 405 (198 in the treatment field group and 207 in the standard arm) comprising the modified intent- to-treat population. The duration of chemotherapy treatment was comparable in both study arms, and patients receiving treatment fields had a median exposure of almost 27 weeks. Statistically significant improvements were observed for several study endpoints, including overall survival (a median of 16.2 versus 14.2 months), distant PFS (at 13.9 versus 11.5 months) and pain-free survival (at 15.2 versus 9.1 months), all in favor of the treatment fields arm. Although quality of life data were not reported in detail, the authors noted a significant improvement in global health status in the treatment fields arm. Safety data showed a higher level of skin adverse events in the treatment fields arm but were otherwise as expected for the GnP combination. These are quite remarkable results which add to the growing evidence base for tumor treatment fields and are particularly compelling in this patient group given the substantial improvement in pain-free survival. It will be especially interesting to see the mature analysis of the quality-of-life endpoints in a subsequent report. The final selection today is Abstract 6001, which describes the C-POST trial, a phase 3 trial of adjuvant cemiplimab versus placebo in patients with high-risk cutaneous squamous cell carcinoma of the skin. This study was presented by Dr. Danny Rischin from the Peter MacCallum Cancer Centre in Melbourne, Australia. Although surgical resection with or without adjuvant radiation is curative in 90% of patients with cutaneous squamous cell carcinoma, high-risk features, including nodal disease, skin and subcutaneous metastases, perineural invasion and bone involvement, predict for an inferior prognosis. Cemiplimab, a PD-1 targeting antibody is standard therapy for patients with locally advanced or metastatic disease who are not candidates for curative surgical resection or radiation therapy, with an overall response rate of almost 50%. The C-POST study evaluated the use of cemiplimab as adjuvant therapy following surgery and radiation in high-risk patients, compared with placebo. Treatment was administered at 3-week intervals for 12 weeks, and then 6-week intervals for a further 36 weeks, with a primary endpoint of disease-free survival. Four hundred and fifteen patients were randomized in the study, 209 to cemiplimab and 206 to placebo. With median follow-up at 24 months, Dr. Rischin reported a highly significant improvement in disease-free survival for the cemiplimab arm, 49.4 months for placebo versus not reached for cemiplimab, with improvements also observed in the rates of locoregional recurrence and distant recurrence at 80% and 60% reductions, respectively. No new safety signals were observed. This study is potentially practice-changing and provides strong evidence that cemiplimab should be considered the new standard of care in this clinical context. Thanks for listening today and join me again tomorrow to hear more top takeaways from ASCO25. If you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speaker: Dr. John Sweetenham Follow ASCO on social media: @ASCO on Twitter @ASCO on Bluesky ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. John Sweetenham: No relationships to disclose
Daily Soap Opera Spoilers by Soap Dirt (GH, Y&R, B&B, and DOOL)
Click to Subscribe: https://bit.ly/Youtube-Subscribe-SoapDirt Bold and the Beautiful spoilers for June 2-6, 2025 see Luna Nozawa (Lisa Yamada) will be at the center of the chaos with her lustful advances towards Will Spencer (Crew Morrow) and a possible murder plot. Liam Spencer's (Scott Clifton) health takes a concerning turn on the CBS soap opera. B&B spoilers see Hope Logan (Annika Noelle) shockingly accepts Carter Walton's (Lawrence Saint-Victor) proposal. The news of their engagement will soon reach Brooke Logan (Katherine Kelly Lang), who is ecstatic and immediately starts planning a celebration. Ridge Forrester (Thorsten Kaye) and Steffy Forrester (Jacqueline MacInnes Wood) express reservations about Hope and Carter's sudden reunion. Spoilers for Bold and Beautiful see Luna continues her pursuit of Will, which escalates to a full-blown brawl with Electra Forrester (Laneya Grace). This might signal Lisa Yamada's temporary exit from the show. Sheila Carter (Kimberlin Brown) warns Luna against making past mistakes and even suggests Luna leave town. Sheila's concern for her granddaughter's actions heightens as Luna suggests eliminating Steffy, which Sheila does not agree with. Hope and Carter plan their wedding, while Brooke struggles with Ridge's absence in her life the week of 6/2 - 6/6/2025. Visit our Bold and the Beautiful section of Soap Dirt: https://soapdirt.com/category/bold-and-the-beautiful/ Listen to our Podcasts: https://soapdirt.podbean.com/ Check out our always up-to-date Bold and the Beautiful Spoilers page at: https://soapdirt.com/bold-and-the-beautiful-spoilers/ Check Out our Social Media... Twitter: https://twitter.com/SoapDirtTV Facebook: https://www.facebook.com/SoapDirt Pinterest: https://www.pinterest.com/soapdirt/ TikTok: https://www.tiktok.com/@soapdirt Instagram: https://www.instagram.com/soapdirt/
In this podcast episode, host Ruchika Talwar, MD, is joined by Amin Mazloom, PhD, Senior Vice President of Bioinformatics, Biostatistics & Data Innovation, and Janine LoBello, DO, Senior Clinical Laboratory Medical Director at Exact Sciences to discuss patient-matched tumor-normal (PMTN) sequencing and why it matters for oncologists. Drs. Mazloom and LoBello discuss PMTN sequencing as a gold standard method for calculating tumor mutational burden and personalized therapy selection and share their thoughts on the future of cancer testing.
In this podcast episode, host Ruchika Talwar, MD, is joined by Amin Mazloom, PhD, Senior Vice President of Bioinformatics, Biostatistics & Data Innovation, and Janine LoBello, DO, Senior Clinical Laboratory Medical Director at Exact Sciences to discuss patient-matched tumor-normal (PMTN) sequencing and why it matters for oncologists. Drs. Mazloom and LoBello discuss PMTN sequencing as a gold standard method for calculating tumor mutational burden and personalized therapy selection and share their thoughts on the future of cancer testing.
Beating Cancer Daily with Saranne Rothberg ~ Stage IV Cancer Survivor
In today's episode, Saranne, the founder of the Comedy Cures Foundation, shares her unique perspective on humor and cancer treatment. She introduces the "Tumor Humor" concept and how she developed her comic perspective while undergoing cancer treatment. Saranne shares a humorous joke about her blood test results and explains the inspiration behind it. She encourages listeners to find the comedic elements in their own cancer journey and invites them to share their jokes or stories with the Comedy Cures Foundation. Join Saranne as she explores the intersection of laughter and healing in the face of cancer.Ranked the Top 5 Best Cancer Podcasts by CancerCare News in 2024 & 2025, and #1 Rated Cancer Survivor Podcast by FeedSpot in 2024 Beating Cancer Daily is listened to in over 130 countries on 7 continents and has over 365 original daily episodes hosted by Stage IV survivor Saranne Rothberg! To learn more about Host Saranne Rothberg and The ComedyCures Foundation:https://www.comedycures.org/ To write to Saranne or a guest:https://www.comedycures.org/contact-8 To record a message to Saranne or a guest:https://www.speakpipe.com/BCD_Comments_Suggestions To sign up for the free Health Builder Series live on Zoom with Saranne and Jacqui, go to The ComedyCures Foundation's homepage:https://www.comedycures.org/ Please support the creation of more original episodes of Beating Cancer Daily and other free ComedyCures Foundation programs with a tax-deductible contribution:http://bit.ly/ComedyCuresDonate THANK YOU! Please tell a friend whom we may help, and please support us with a beautiful review. Have a blessed day! Saranne
¿Vds se acuerdan de en qué pensaban cuando volvieron de una anestesia? Hay gente que regresa a la consciencia diciendo palabrotas, insultando, o con una enorme felicidad, o llorando, o destapando verdades y secretos, que también se ha dado el caso.Hace un año Sergio volvió del quirófano pensando en flores.Sergio Ruiz es Policía Nacional y ha trabajado la mayor parte de su carrera como guía canino en Zaragoza. Hace un año se le diagnosticó un tumor cerebral y, al volver a vestirse con el uniforme, se quiso pasar a dar las gracias por el Miguel Servet a todo el personal sanitario que estuvo a su lado.Vio flores al ir volviendo de la anestesia.Sergio ha ido al Hospital con un puñado de ellas, cada una en su maceta, para todos los profesionales sanitarios que le atendieron aquellos días en los que ni él mismo sabía bien qué le estaba pasando.Las flores en el subconsciente de Sergio ya están en las manos de los que han permitido que vuelva a sentirse ...
Johann Ilgenfritz's life changed in 2011 when he had a heart attack and six months later was diagnosed with cancer. After unsuccessful Radio Therapy he researched for a cure, soon realizing that that there was no central point for reliable online health information. He decided to create a platform and launched UK Health Radio, while still fighting cancer. After overcoming cancer through nutritional and lifestyle changes, he earned the title "The Curator of Health Expertise" from the press. His guiding principle is simple: "Good health is a choice." Initially, he saw cancer as the root of his illness but later realized it was merely a symptom of an already unwell body. He understood that by addressing the underlying cause, he could transform the outcome. With this vision, UK Health Radio (https://ukhealthradio.com/) has embraced a clear mission: to inspire and empower people to take responsibility for their own health. This does not mean taking your health into your own hands, but to be part of the process of attaining and/or keeping your health freedom. It is all about being informed, being empowered, taking action and being healthy! UK Health Radio delivers information through 41 shows airing 24/7, reaching over 1.5 million very dedicated listeners and is now also available on 11 podcast platforms worldwide. In February of 2024, Johann created The Alkaline Collective Mastermind (https://alkaline-collective.com/), a dedicated online community for those battling cancer, aiming to prevent it, or striving to stop it's recurrence. Designed for individuals who are committed to hold themselves accountable, and seek a comprehensive toolbox of resources.
In this episode, we review the high-yield topic of Islet Cell Tumors from the Gastrointestinal section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
In this episode of the Hand Surgery Resource Podcast, Dr. Larry Hurst shares more about Giant Cell Tumor of the Tendon Sheath, more popularly known as Xanthoma.A giant cell tumor of the tendon sheath (GCTTS) is a slow growing, usually painless benign lesion localized at the extremities. It is the second most common benign tumor of the hand after ganglion cyst.Find out more about it here: https://www.handsurgeryresource.net/xanthoma
Biden's malignant metastatic tumor must be given everything it needs to defend itself from unprovoked attacks by radical oncologists. Reading by Tim Foley.
INE aprueba estrategia en caso de empate en elecciones del Poder JudicialEn Chihuahua extirpan tumor de más de dos kilogramos a mujer embarazadaLa única manera de avanzar en la paz es un diálogo entre Trump y Putin: Marco Rubio Más información en nuestro Podcast
Send us a textIn this Journal of Vascular and Interventional Radiology (JVIR) audio episode, JVIR blog Editor Peter Li, MD, MS, uses artificial intelligence (AI) platform ElevenLabs to produce a podcast discussion on the November 2024 JVIR paper, "Using Voxel-Based Dosimetry to Evaluate Sphere Concentration and Tumor Dose in Hepatocellular Carcinoma Treated with Yttrium-90 Radiation Segmentectomy with Glass Microspheres."Related resources:Read the original articleRead the blog entry, "Vox Voxel: Calculating Y90 Tumor Dose and Sphere Distribution with Voxel Dosimetry"SIR thanks BD for its generous support of the Kinked Wire.Contact us with your ideas and questions, or read more about about interventional radiology in IR Quarterly magazine or SIR's Patient Center.(c) Society of Interventional Radiology.Support the show
Kathleen investigates reports that methylene blue may shrink cancerous tumours. Peter talks about future guests and our featured author. Kathleen's Deep Dive Kathleen discusses a report from Dr. Mercola which explores the anticancer properties of Methylene Blue, a synthetic compound traditionally used as a dye and in medical treatments. It highlights research indicating that Methylene Blue may have the potential to target cancer cells through mechanisms such as inducing apoptosis and inhibiting tumour growth. The article likely reviews studies and clinical findings to evaluate its efficacy and safety as an adjunct or alternative cancer therapy. It aims to inform readers about the current scientific understanding and future research directions regarding Methylene Blue's role in oncology. The article is at the link in the "mentioned On The Show" section below. This Week's Health Tip Kathleen spoke about Dr. Morse's Ultimate Detox Kit and following a diet of raw fruit and vegetables. She explains the transformative power of the Ultimate Detox Kit and fasting program as it guides your body's natural detoxification process to unclog all channels of elimination, flush toxins from the system, and revitalize the body's organ systems and functions. The Ultimate Detox is a 16-week program that includes 9 rotating detoxification formulas, with fasting and lifestyle recommendations. Health Declassified is brought to you by Peter Wright & Kathleen Beauvais contact us to be a guest on our show. https://HealthDeclassified.com peter@healthdeclassified.com kathleen@healthdeclassified.com Get our weekly newsletter for news of future guests. Subscribe here Our Affiliate Suppliers Dr. Morse's Herbal Health Club Remedies https://bit.ly/3Oc2J8L Science Driven Supplements - Circuguard & OxyBoost https://bit.ly/3VPzsV8 MyWayCBD https://bit.ly/4jFzmd0 BAM Metrics Exercise Equipment https://bit.ly/3SMnZom B3 Sciences BFR bands https://bit.ly/4g9HmzV Chatterboss Virtual Assistants https://bit.ly/3Obmzlb Follow us on social media Spotify https://open.spotify.com/show/1N3yM4lUuBYGMByhwuUDVy Facebook Group https://www.facebook.com/groups/480434235068451 FaceBook Page https://www.facebook.com/HealthDeclassified Twitter X https://x.com/HealthDeclass Instagram https://www.instagram.com/healthdeclassified/ Here are some of the tools we use to produce this podcast. Kit for sending emails and caring for subscribers Hostgator for website hosting. Podbean for podcast hosting Airtable for organizing our guest bookings and automations. Clicking on some links on this site will let you buy products and services which may result in us receiving a commission, however, it will not affect the price you pay.
In dieser Folge ist Ingwar Perowanowitsch zu Gast. Er ist Politikwissenschaftler, freier Journalist und leidenschaftlicher Radreisender. Wir reden über sogenannte "Donauschwaben", Politisierung durch Radeln und warum Deutschland sich so schwertut, fahrrad- und umweltgerechtere Städte zu planen. Über sein Gefühl der Bonus-Lebenszeit, überemotionale Männer mit starken Auto-Biografien und was ihm beim Radfahren durch muslimische Länder aufgefallen ist. Ingwars Film "Mit dem FAHRRAD nach ASERBAIDSCHAN 4K" https://www.youtube.com/watch?v=N9ImVqRloWs (03:20) Passkontrolle (09:25) Klischee-Check (25:45) Analoges Aufwachsen, Durchmogeln & Entführt im Sommer (45:40) Tumor im Knie: "Ich bin jeden Tag dankbar" (55:20) Politisierung durch Radwege, Auto-Biografie & Revolution der Städte (1:34:05) Radreise nach Baku: Reiseprivilegien & Gespräche über Gott und die Welt "OUT OF TIBET" PODCAST von Namri Dagyab https://open.spotify.com/show/3qpuT338hjIvOTWbAhq0cv?si=aaff318936b04699 CIVIS-MEDIENPREIS LIVE: https://www.civismedia.eu/medienpreis/medienpreis-2025/livestream/ SUPPORT: Halbe Katoffl unterstützen: https://halbekatoffl.de/unterstuetzen/ Paypal: frank@halbekatoffl.de Steady: https://steadyhq.com/de/halbekatoffl/about Überweisung/ Dauerauftrag: Schreib an frank@halbekatoffl.de | Stichwort: KONTO
Got Health Questions or Comments?
Beating Cancer Daily with Saranne Rothberg ~ Stage IV Cancer Survivor
Today on Beating Cancer Daily, Saranne brings a light-hearted and uplifting perspective to the challenging journey of cancer patients by sharing her innovative approach to humor through her experience with Stage IV cancer. From being a patient herself to founding the Comedy Cures Foundation, Saranne provides a unique narrative filled with tumor humor, specifically focusing on the often arduous but necessary cancer scans. Saranne recounts a personal, humorous anecdote about confusing airport security scans with medical scans, offering listeners a chance to laugh and view their own cancer experiences from a comic perspective.Ranked the Top 5 Best Cancer Podcasts by CancerCare News in 2024 & 2025, and #1 Rated Cancer Survivor Podcast by FeedSpot in 2024 Beating Cancer Daily is listened to in over 130 countries on 7 continents and has over 365 original daily episodes hosted by Stage IV survivor Saranne Rothberg! To learn more about Host Saranne Rothberg and The ComedyCures Foundation:https://www.comedycures.org/ To write to Saranne or a guest:https://www.comedycures.org/contact-8 To record a message to Saranne or a guest:https://www.speakpipe.com/BCD_Comments_Suggestions To sign up for the free Health Builder Series live on Zoom with Saranne and Jacqui, go to The ComedyCures Foundation's homepage:https://www.comedycures.org/ Please support the creation of more original episodes of Beating Cancer Daily and other free ComedyCures Foundation programs with a tax-deductible contribution:http://bit.ly/ComedyCuresDonate THANK YOU! Please tell a friend whom we may help, and please support us with a beautiful review. Have a blessed day! Saranne
El líder del Caucus Hispano y otros dos congresistas visitaron a la familia en México; Espaillat detalla cómo buscan ayudar a la niña enferma y a sus padres.
BUFFALO, NY - May 9, 2025 – A new #research paper was #published in Oncotarget, Volume 16, on May 8, 2025, titled “METTL3 promotes oral squamous cell carcinoma by regulating miR-146a-5p/SMAD4 axis." In this study, researchers Jayasree Peroth Jayaprakash, Pragati Karemore, and Piyush Khandelia from the Birla Institute of Technology and Science, India, discovered that a molecule called METTL3 contributes to the development and spread of oral squamous cell carcinoma (OSCC). The study shows that METTL3 increases the levels of a small RNA molecule called miR-146a-5p, which blocks SMAD4, a key tumor-suppressing gene. These findings help explain why oral cancers are difficult to treat and may offer a new target for more effective therapies. Oral squamous cell carcinoma is a common and aggressive cancer affecting the mouth and throat. It has a high death rate, mainly due to late detection, treatment resistance, and the cancer's ability to invade nearby tissues. In this study, the researchers focused on METTL3, an enzyme that adds chemical tags known as m6A marks to RNA, which change how genetic information is used by cells. They found that METTL3 is unusually active in OSCC cells, causing an increase in miR-146a-5p. This molecule, in turn, blocks the function of SMAD4, which helps control how cells grow and die in our bodies. “METTL3, the primary m6A RNA methyltransferase, is significantly upregulated in OSCC cells leading to increased global m6A levels.” When METTL3 was reduced or chemically blocked, miR-146a-5p levels dropped and SMAD4 levels increased. This shift slowed the growth of cancer cells, increased their death, and made them less likely to spread. When researchers reintroduced miR-146a-5p or lowered SMAD4 levels again, the cancer-promoting behavior returned. These results show that the METTL3–miR-146a-5p–SMAD4 pathway plays a key role in OSCC. The findings open up new possibilities for treatment. Drugs that block METTL3 or miR-146a-5p or that restore SMAD4 could slow or stop tumor growth. One such drug, STM2457, which targets METTL3, has already shown promise in lab studies. As research progresses, targeting this molecular pathway may offer a new strategy in treating OSCC. This discovery improves our understanding of how OSCC develops and avoids the body's defenses. By interfering with this newly discovered pathway, future treatments may become more successful, improving survival rates and quality of life for people with this disease. DOI - https://doi.org/10.18632/oncotarget.28717 Correspondence to - Piyush Khandelia - piyush.khandelia@hyderabad.bits-pilani.ac.in Video short - https://www.youtube.com/watch?v=o5XuDlcIma8 Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28717 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
In this radiology lecture, we review the ultrasound appearance of giant cell tumor of the tendon sheath! Key teaching points The post Ultrasound of Giant Cell Tumor of the Tendon Sheath appeared first on Radquarters.
Show #2405 Show Notes: Luke 8: https://www.biblegateway.com/passage/?search=Luke%208&version=KJV ‘Manifest’: https://webstersdictionary1828.com/Dictionary/manifest LAN Events: https://thelibertyactionnetwork.com/calendar/ Mathematics of the Mound Builders: https://www.youtube.com/watch?v=NZDYuo2bGrM Parasites in Tumor: https://www.facebook.com/reel/919497673449737 Cancer-Fighting benefits of Ivermectin: https://choiceclips.whatfinger.com/2025/05/07/the-remarkable-cancer-fighting-benefits-of-ivermectin-ivermectin-can-actually-kill-cancer-stem-cells-which-are-often-resistant-to-chemotherapy/ New Cancer Treatment Protocol: https://www.thegatewaypundit.com/2024/10/new-cancer-treatment-protocol-featuring-horse-dewormer-ivermectin/ Government Admits it knew covid […]
Dr. Jason Williams, President and Director of Interventional Oncology and Immunotherapy at the Williams Cancer Institute, uses a combination of Pulse Electric Field technology to ablate tumors and direct injection of immunotherapy drugs into the tumor to stimulate the immune system. This approach can be used in conjunction with traditional cancer treatments and has fewer side effects than standard immunotherapy. This method is part of the broader trend in cancer research to provide a more targeted approach to treating tumors. Jason explains, "Our big focus is going to the tumor itself, so we do treatments directly at the tumor, and we do a combination of things. We do things that will be considered ablation where we're using different technologies or energies — I'll explain — particularly, we use one called Pulse Electric Field (PEF), which kills the tumor by essentially shocking it, and that kills it in a way that actually makes the immune system see it better. You're not trying to kill all of the tumor, you're trying to kill pieces for the immune system. Then we inject drugs into that area of the tumor, particularly immunotherapy drugs, but it can be other drugs as well, and just really taking the fight to the cancer right in the tumor." "I think that our mistake in cancer treatments is that we're not addressing the tumors directly. I mean, it's one thing to expect that you're going to take a drug orally or intravenously and that it's going to arrive and make it to the cancer cells. Still, the other way is to go right into it, putting the drugs there, and particularly with immunotherapies, where you want to attract the immune system to it. You want those drugs in the cancer, you don't want them just everywhere in the body." #WilliamsCancer #Cancer #Oncology #Tumors #Immunotherapy #PulseElectricField #ImmuneSystem #TargetingTumors WilliamsCancerInstitute.com Download the transcript here
This episode summarizes recent updates on: Tumor infiltrating clonal hematopoiesis (TI-CH) and its apparent negative impact on solid tumors (https://www.nejm.org/doi/full/10.1056/NEJMoa2413361) Updated dostarlimab data on MMRd use in rectal cancer and other solid tumors in the neoadjuvant (definitive?!?!) setting (https://www.nejm.org/doi/full/10.1056/NEJMoa2404512) Phase 1 study of 7 + 3 + Venetoclax (https://doi.org/10.1182/blood.2024026700) Zongertinib, a new HER2 TKI (https://www.nejm.org/doi/full/10.1056/NEJMoa2503704)
You'll have no Kimchi, no horseradish and no Lt. Yar! Copycat Dipshitter. Tumor fruit. Port a Potty Perks. Shriracha Schmear. Gotta Go At Costco. Ass Cheek to Ass Cheek. I Dream Of GKneeeeeeeeeeeeeeeeeeeeeeeeeeeee! Neither a Miracle, Nor a Whip. Runner butt poo. Friendly Wackadoo. Non-Organic Dipshits. The darker the berry the hotter it is. John Wayne's Sperm. Tech Time with Mr. Las Vegas Tom Merritt. Alicia Stockholm Recommentals with Randy and Nicole and more on this episode of The Morning Stream. Hosted on Acast. See acast.com/privacy for more information.
You'll have no Kimchi, no horseradish and no Lt. Yar! Copycat Dipshitter. Tumor fruit. Port a Potty Perks. Shriracha Schmear. Gotta Go At Costco. Ass Cheek to Ass Cheek. I Dream Of GKneeeeeeeeeeeeeeeeeeeeeeeeeeeee! Neither a Miracle, Nor a Whip. Runner butt poo. Friendly Wackadoo. Non-Organic Dipshits. The darker the berry the hotter it is. John Wayne's Sperm. Tech Time with Mr. Las Vegas Tom Merritt. Alicia Stockholm Recommentals with Randy and Nicole and more on this episode of The Morning Stream. Hosted on Acast. See acast.com/privacy for more information.
Lona Twins Talk All: Twin Sisters, Learning Disability, Mental Health, Tumor, CHISME & MORE!! Thanks to my sponsors: Find exactly what you're booking for on https://Booking.com, Booking.YEAH! • Don't forget to subscribe to the podcast for free wherever you're listening or by using this link: https://bit.ly/NochedePendejadasPodcast • If you like the show, telling a friend about it would be helpful! You can text, email, Tweet, or send this link to a friend: https://bit.ly/NochedePendejadasPodcast Follow Alannized on IG Follow Alannized on TikTok Follow Alannized on Twitter Learn more about your ad choices. Visit podcastchoices.com/adchoices
Could your body shrink a brain tumor by half before surgery? Taylor Dukes is proof that it is possible. In this episode, Taylor shares her journey from medical mission trips in Africa to discovering a plum-sized brain tumor in her frontal lobe with no symptoms, which offers invaluable wisdom for anyone navigating their own health challenges. Rather than immediately rushing to surgery, she practiced an integrative approach — metabolic ketosis, methylene blue, red light therapy, and molecular hydrogen oxygen, and with the results being nothing short of remarkable, her tumor shrinking by half before surgery. Your body's healing capacity is extraordinary when given the right tools. The question is: are you ready to discover what's possible for your own health? Join the Ultimate Human VIP community and gain exclusive access to Gary Brecka's proven wellness protocols today!: https://bit.ly/4ai0Xwg Connect with Taylor Dukes: Website: https://bit.ly/4byxTS5 Instagram: https://bit.ly/3Rii1cS TikTok: https://bit.ly/4hiQaEe Facebook: https://bit.ly/4iUS5zL LinkedIn: https://bit.ly/4kW5hGq Thank you to our partners: H2TABS - USE CODE “ULTIMATE10” FOR 10% OFF: https://bit.ly/4hMNdgg BODYHEALTH - USE CODE “ULTIMATE20” FOR 20% OFF: http://bit.ly/4e5IjsV BAJA GOLD - USE CODE "ULTIMATE10" FOR 10% OFF: https://bit.ly/3WSBqUa EIGHT SLEEP - SAVE $350 ON THE POD 4 ULTRA WITH CODE “GARY”: https://bit.ly/3WkLd6E COLD LIFE - THE ULTIMATE HUMAN PLUNGE: https://bit.ly/4eULUKp WHOOP - GET 1 FREE MONTH WHEN YOU JOIN!: https://bit.ly/3VQ0nzW MASA CHIPS - GET 20% OFF YOUR FIRST $50+ ORDER: https://bit.ly/40LVY4y VANDY - USE CODE “ULTIMATE20” FOR 20% OFF: https://bit.ly/49Qr7WE PARKER PASTURES - PREMIUM GRASS-FED MEATS: https://bit.ly/4hHcbhc AION - USE CODE “ULTIMATE10” FOR 10% OFF: https://bit.ly/4h6KHAD HAPBEE - FEEL BETTER & PERFORM AT YOUR BEST: https://bit.ly/4a6glfo CARAWAY - USE CODE “ULTIMATE” FOR 10% OFF: https://bit.ly/3Q1VmkC HEALF - GET 10% OFF YOUR ORDER: https://bit.ly/41HJg6S BIOPTIMIZERS - USE CODE “ULTIMATE” FOR 10% OFF: https://bit.ly/4inFfd7 RHO NUTRITION - USE CODE “ULTIMATE15” FOR 15% OFF: https://bit.ly/44fFza0 Watch the “Ultimate Human Podcast” every Tuesday & Thursday at 9AM EST: YouTube: https://bit.ly/3RPQYX8 Podcasts: https://bit.ly/3RQftU0 Connect with Gary Brecka: Instagram: https://bit.ly/3RPpnFs TikTok: https://bit.ly/4coJ8fo X.com: https://bit.ly/3Opc8tf Facebook: https://bit.ly/464VA1H LinkedIn: https://bit.ly/4hH7Ri2 Website: https://bit.ly/4eLDbdU Merch: https://bit.ly/4aBpOM1 Newsletter: https://bit.ly/47ejrws Ask Gary: https://bit.ly/3PEAJuG Timestamps: 00:00 Intro 02:49 Taylor Dukes' Health Journey 1.0 10:28 Journey 2.0: Diagnosis and Healing from a Brain Tumor 19:28 Impact of Mindset and Healthy Diet 23:35 Undergoing through Different Treatments (Vitamin C, Methylene Blue Infusions, Red Light Therapy, Molecular Hydrogen Oxygen, and Metabolic Ketosis) 26:13 Elimination of Mold, Mycotoxin, Metals, and Virus 27:19 Link of Parasites and Cancer 30:52 Shrinkage of the Tumor in Half 34:55 Treating Lyme Disease 37:01 Stress-Reducing Techniques 41:05 Caring for Our Gut Health 44:48 Practical Steps Every Mom Should Know About 52:58 Taylor's Online Community 54:50 Final Question: What does it mean to you to be an “Ultimate Human?” The Ultimate Human with Gary Brecka Podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user's own risk. The Content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions. Learn more about your ad choices. Visit megaphone.fm/adchoices